A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome

International Journal of Hematology

Volumn 90, Issue 4, 2009, Pages 492-500

  Kikuchi, Akira ^a,b   Kigasawa, Hisato ^c   Tsurusawa, Masahito ^d   Kawa, Keisei ^e   Kikuta, Atsushi ^f   Tsuchida, Masahiro ^g   Nagatoshi, Yoshihisa ^h   Asami, Keiko ⁱ   Horibe, Keizo ^j   Makimoto, Atsushi ^k   Tsukimoto, Ichiro ^l  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^d AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^g Ibaraki Children's Hospital   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL   (Japan)

^l SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

more..

Author keywords

Hematologic malignancies; Hyperuricemia; Pediatric; Rasburicase; Tumor lysis syndrome (TLS)

Indexed keywords

CORTICOSTEROID; RASBURICASE; SR 29142; UNCLASSIFIED DRUG; URIC ACID;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERURICEMIA; INFANT; JAPANESE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERURICEMIA; INFANT; MALE; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID;

EID: 73449109809     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0402-6     Document Type: Article

References (26)

1. C Ronco P Inguaggiato V Bordonia M De Cal M Bonello E Andrikos, et al. 2005 Rasburicase therapy in acute hyperuricemia and renal dysfunction Contrib Nephrol. 147 115 123 1:CAS:528:DC%2BD2MXhtVegu7fM 15604611
2. DP Jones FB Stapleton D Kalwinsky CP McKay SJ Kellie CH Pui 1990 Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia Med Pediatr Oncol. 18 283 286 10.1002/mpo.2950180405 1:STN:280:DyaK3c3os12ruw%3D%3D 2355888 (Pubitemid 20219919)
3. K Arrambide RD Toto 1993 Tumor lysis syndrome Semin Nephrol. 13 273 280 1:STN:280:DyaK3szhtVemtQ%3D%3D 8321927
4. MB Davidson S Thakkar JK Hix ND Bhandarkar A Wong MJ Schreiber 2004 Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome Am J Med. 116 546 554 10.1016/j.amjmed.2003.09.045 1:CAS:528:DC%2BD2cXivVWrtrg%3D 15063817 (Pubitemid 38452647)
5. LF Cohen JE Balow IT Magrath DG Poplack JL Ziegler 1980 Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma Am J Med 68 486 491 10.1016/0002-9343(80)90286-7 1:STN:280:DyaL3c7nt1GrtQ%3D%3D 7369230
6. FB Stapleton DR Strother S Roy RJ Wyatt CP McKay SB Murphy 1988 Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma Pediatrics. 82 863 869 1:STN:280: DyaL1M%2FktFCnsA%3D%3D 3186376
7. WP Bowman JJ Shuster B Cook T Griffin F Behm J Pullen, et al. 1996 Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study J Clin Oncol. 14 1252 1261 1:STN:280:DyaK283ktlSruw%3D%3D 8648381
8. BD Cheson BS Dutcher 2005 Managing malignancy-associated hyperuricemia with rasburicase J Support Oncol. 3 117 124 1:CAS:528:DC%2BD2MXjtVeltrc%3D 15796443
9. AR Sood LD Burry DK Cheng 2007 Clarifying the role of rasburicase in tumor lysis syndrome Pharmacotherapy. 27 111 121 10.1592/phco.27.1.111 1:CAS:528:DC%2BD2sXhsVOltrY%3D 17192165 (Pubitemid 46067966)
10. R Legoux B Delpech X Dumont J-C Guillemot P Ramond D Shire, et al. 1992 Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase J Biol Chem. 267 8565 8570 1:CAS:528:DyaK38Xks1ehtbY%3D 1339455
11. V Oldfield CM Perry 2006 Spotlight on rasburicase in anticancer therapy-induced hyperuricemia BioDrugs. 20 197 199 10.2165/00063030-200620030- 00008 1:CAS:528:DC%2BD2sXhtV2rtrvF 16724869
12. SC Goldman JS Holcenberg JZ Finklestein R Hutchinson S Kreissman FL Johnson, et al. 2001 A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis Blood. 97 2998 3003 10.1182/blood.V97.10.2998 1:CAS:528:DC%2BD3MXjsl2rtb8%3D 11342423
13. O Bessmertny LM Robitaille MS Cairo 2005 Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome Curr Pharm Des. 11 4177 4185 10.2174/138161205774913291 1:CAS:528:DC%2BD2MXht1KgtrbO 16375739 (Pubitemid 41672466)
14. Ishizawa K, Ogura M, Hamaguchi M, Hotta T, Ohnishi K, Sasaki T, et al. Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci. 2008 Dec 14. [Epub ahead of print].
15. FA Graybill C Wang 1980 Confidence intervals on nonnegative linear combinations of variances J Am Stat Assoc. 75 869 873 10.2307/2287174
16. N Kizer E Martinez M Powell 2006 Report of two cases of rasburicase-induced methemoglobinemia Leuk Lymphoma. 47 2648 2650 10.1080/10428190600967204 1:CAS:528:DC%2BD2sXitFWiu7Y%3D 17169811 (Pubitemid 44932657)
17. CH Pui S Jeha D Irwin B Camitta 2001 Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial Leukemia. 15 1505 1509 10.1038/sj.leu.2402235 1:CAS:528: DC%2BD3MXnvF2mtb8%3D 11587206 (Pubitemid 32994667)
18. A Bosly A Sonet CR Pinkerton G McCowage D Bron MA Sanz, et al. 2003 Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study Cancer. 98 1048 1054 10.1002/cncr.11612 1:CAS:528:DC%2BD3sXns1Sjsbo%3D 12942574 (Pubitemid 37022107)
19. ™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial Leukemia. 19 34 38 1:CAS:528:DC%2BD2cXhtVKnsb3K 15510203
20. HY Shin HJ Kang ES Park HS Choi HS Ahn SY Kim, et al. 2006 Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea Pediatr Blood Cancer. 46 439 445 10.1002/pbc.20555 16123985 (Pubitemid 43334649)
21. L-Y Wang LY Shih H Chang ST Jou KH Lin TC Yeh, et al. 2006 Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies Acta Haematol. 115 35 38 10.1159/000089463 1:CAS:528:DC%2BD28XlvV2ktA%3D%3D 16424647 (Pubitemid 43130430)
22. B Coiffier A Altman CH Pui A Younes MS Cairo 2008 Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review J Clin Oncol. 26 2767 2778 10.1200/JCO.2007.15.0177 1:CAS:528: DC%2BD1cXnvVOhtrs%3D 18509186
23. Y Bertrand F Mechinaud B Brethon V Mialou A Auvrignon B Nelken, et al. 2008 for SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey J Pediatr Hematol Oncol. 30 267 271 10.1097/MPH.0b013e318162bd41 18391694
24. I Rényi E Bárdi E Udvardi G Kovács K Bartyik P Kajtár, et al. 2007 Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma Pathol Oncol Res. 13 57 62 10.1007/BF02893442 17387390
25. CH Pui 2002 Rasburicase: a potent uricolytic agent Expert Opin Pharmacother. 3 433 442 10.1517/14656566.3.4.433 1:CAS:528:DC%2BD38Xjs1ehsrk%3D 11934348 (Pubitemid 34450152)
26. CH Pui HH Mahmoud JM Wiley GM Woods G Leverger B Camitta, et al. 2001 Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma J Clin Oncol. 19 697 704 1:CAS:528: DC%2BD3MXhtlGrtrc%3D 11157020